Insight Molecular Diagnostics Inc. Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss
Insight Molecular Diagnostics Inc. (IMDX) reported Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-24.
Financial Statements › Income Statement › Other Income
us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments · last filed 2025-03-24
- Insight Molecular Diagnostics Inc. marketable securities, gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2023-12-31 was -$69.00K.
- Insight Molecular Diagnostics Inc. marketable securities, gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2023-09-30 was -$89.00K.
- Insight Molecular Diagnostics Inc. marketable securities, gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2023-06-30 was -$24.00K.
- Insight Molecular Diagnostics Inc. marketable securities, gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2023-03-31 was $121.00K.
- Insight Molecular Diagnostics Inc. marketable securities, gain (loss), excluding other-than-temporary impairment loss for fiscal 2024 was $0.00.
- Insight Molecular Diagnostics Inc. marketable securities, gain (loss), excluding other-than-temporary impairment loss for fiscal 2023 was -$61.00K.
- Insight Molecular Diagnostics Inc. marketable securities, gain (loss), excluding other-than-temporary impairment loss for fiscal 2022 was -$471.00K.
| Period end | Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss 3 month | Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss 6 month | Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss 9 month | Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-24 | |||
| 2023-12-31 | -$69.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | -$158.00K derived: sum of 2 quarters · filed 2025-03-24 | -$182.00K derived: sum of 3 quarters · filed 2025-03-24 | -$61.00K 10-K · filed 2025-03-24 |
| 2023-09-30 | -$89.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$113.00K derived: sum of 2 quarters · filed 2024-11-12 | $8.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | -$24.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $97.00K 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $121.00K 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | -$471.00K 10-K · filed 2024-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |